1-4 of 4
Hilary Rosenthal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL).

Christopher Flowers, Hilary Rosenthal, Jennifer Brown, Wendy Stock, Harvey Katzen, Shailendra Lakhanpal, David Jaye
Journal: Blood
Blood (2007) 110 (11): 3111.
https://doi.org/10.1182/blood.V110.11.3111.3111
Published: 2007
Journal Articles

Patulin: A Small Molecule Mycotoxin Possessing Potent Selective In Vitro Cytotoxicity Against Malignant T-Cells.

Margo R. Rollins, BS, Alex Hessel, Hilary Rosenthal, M.T., Ned Waller, M.D. Ph.D
Journal: Blood
Blood (2006) 108 (11): 4270.
https://doi.org/10.1182/blood.V108.11.4270.4270
Published: 2006
Journal Articles

Effects of Mycotoxins on Mononuclear Cells (MNCs) in Normal Blood, T-Cell Leukemia and Lymphoma Cell Lines.

Klara R. Klein, Casey S. Woodward, Edmund K. Waller, MD, PhD, Mary Jo Lechowicz, MD, Hilary Rosenthal
Journal: Blood
Blood (2005) 106 (11): 4828.
https://doi.org/10.1182/blood.V106.11.4828.4828
Published: 2005
Journal Articles

Larger numbers of CD4 bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation

Clinical Trials & Observations
Edmund K. Waller, Hilary Rosenthal, Terry W. Jones, Jennifer Peel, Sagar Lonial, Amelia Langston, Istvan Redei, Ingrid Jurickova, Michael W. Boyer
Journal: Blood
Blood (2001) 97 (10): 2948–2956.
https://doi.org/10.1182/blood.V97.10.2948
Published: 2001